Page 6 - Best Brain MRI doctors: TOP 220 doctors

Dr. Victor Alexander Krol - Chief of Gastroenterology, Internal Medicine and Obesity Treatment Center at Martinus Hospital

Dr. Victor Alexander Krol is a highly qualified specialist, heading the departments of gastroenterology and internal medicine. With many years of experience and deep knowledge in his field, Dr. Krol has established himself as an outstanding expert, providing patients with comprehensive treatment and an individual approach. He actively uses the latest methods of diagnosis and treatment of diseases of the gastrointestinal tract, metabolism, as well as diseases of the cardiovascular and respiratory systems.

Dr. Krol is also the director of the certified Obesity Treatment Center at Martinus Hospital, which provides surgical and endoscopic treatments for obesity. The center uses advanced technology to diagnose and treat obesity (adiposis), including methods such as bariatric surgery, endoscopic weight loss, and specialized programs for patients with different stages of obesity. The center is certified to high standards and has excellent results in the treatment of this serious disease.

The Gastroenterology Department, headed by Dr. Krol, diagnoses and treats diseases of the stomach, intestines, liver, pancreas, and gallbladder. The doctors of the department use a wide range of methods, including endoscopic procedures, ultrasound, and other modern diagnostic technologies.

The Department of Internal Medicine covers a wide range of diseases, including cardiology, diabetology, infectology, and therapy of respiratory and renal diseases. Dr. Krol and his team provide a comprehensive approach to treatment using the most advanced methods of medicine.

Thanks to his high professionalism and humane approach to each patient, Dr. Krol deservedly enjoys the respect of colleagues and patients.

Dr. Viola Fox is the Chief Physician at the Clinic for Haematology, Oncology, and Palliative Medicine at BKZ Solingen. This clinic is a certified interdisciplinary cancer center. Dr. Fox is a leading expert in drug therapy for tumor diseases in Germany and Europe. She has more than 15 years of experience in this field.

She is a member of the German Society of Oncology and Haemato-oncology (GDHO), the German Association of Physicians, and the American Association for Cancer Research. Dr. Fox is also active in molecular biology research. Her work supports progress in cancer treatment and molecular diagnostics.

Her main areas of expertise are chemotherapy, immunotherapy, targeted therapy, and radiation therapy. Dr. Fox is known for her innovative methods and strong commitment to patient care. Her efforts have led to high recovery rates and recognition from her peers.

Specialist in Neurology
Head of the Advanced Neurosciences Unit – Quirónsalud

Professional Experience

Head of the Neurology Service
Hospital Universitario de Torrevieja (2018 – 2021)
Led a multidisciplinary neurology team with a focus on patient-centered care, especially for neurodegenerative disorders.

Head of Neurology Service
Hospital Clínica Benidorm (2017 – 2018)
Oversaw diagnostic and therapeutic services in general neurology, epilepsy, and movement disorders.

Consultant Neurologist
Hospital General Universitario de Alicante (2017 – 2018)
Specialized in inpatient and outpatient neurology services, actively participated in teaching and research.

Consultant Neurologist
Hospital de Manises, Valencia (2016 – 2017)
Focus on epilepsy and complex neurological diagnostics.

General Practitioner
Baghavatula Charitable Trust (BCT), Vishakapatnam, India (2012 – 2016)
Provided healthcare services in underserved rural communities, gaining valuable experience in global medicine.

Education & Training

Medical Degree
Universidad Autónoma de Madrid (UAM) (2005 – 2011)

Neurology Residency (MIR Program)
Hospital General Universitario de Alicante (2012 – 2016)

Postgraduate Studies

Postgraduate Specialization in Movement Disorders
Universidad Oberta de Catalunya (2019 – 2020)

Postgraduate Specialization in Clinical Research
Chair UAM-Abbvie (2020 – ongoing)

Master in Healthcare Management
UDIMA - Universidad a Distancia de Madrid (2020 – ongoing)

Master in Clinical Neurology
Universidad Francisco de Vitoria (2020 – ongoing)

Professional Societies

Member of the Valencian Society of Neurology (SVN)

Member of the Spanish Society of Neurology (SEN)

Scientific Contributions

Publications:

"Creutzfeldt-Jakob Disease – Heidenhain Variant" – Presented at the 66th Meeting of the Spanish Society of Neurology (2015)

"Sleepwalking or Epilepsy?" – Presented at the 39th Annual Meeting of the Spanish Society of Neuropediatrics (2016)

Conferences & Courses:

Epilepsy Hospital Stage Course – Hospital La Princesa, Madrid (2020)

Updates on Parkinson’s Disease and Movement Disorders – Movement Disorder Society, 2019

American Epilepsy Society Annual Meeting – Baltimore, USA (2019)

Education & Academic Qualifications

License (MD)

Field: Medicine

University: Istanbul University

Year: 1987

Residency

Field: Cardiovascular Surgery

Institution: Siyami Ersek Heart Center

Years: 1988–1994

Clinical Fellowship

Field: Cardiovascular Surgery

Institution: University of Ottawa Heart Center (Canada)

Years: 1994–1995

Academic Titles & Positions

Assistant Professor

Field: Cardiovascular Surgery

Institution: Siyami Ersek Heart Center

Years: 1995–2008

Professor

Field: Cardiovascular Surgery

Institution: Altınbaş University

Years: 2014–2019

Membership in Scientific and Professional Organizations

-Turkish Society of Cardiovascular Surgery

-European Society for Cardiovascular Surgery

-European Society for Vascular Surgery

Education & Expertise

1996 to 2000 | Dicle University – Medical Education

Professional Experience

2001 to 2006 | Diyarbakır State Hospital – Neurology Specialist

2006 to 2009 | Düzce Atatürk State Hospital – Neurology Specialist

2009 to 2013 | Düzce University – Associate Professor of Neurology

2013 to 2016 | Düzce University – Associate Professor of Neurology

2017 to 2024 | Pendik Private Century Hospital – Associate Professor of Neurology

2024 to Present | VM Medical Park Pendik Hospital – Associate Professor of Neurology

Courses & Certifications

June, 2012 | Trainer Training Course

February, 2010 | Trainer Training Course

March, 2011 | Sleep Medicine Certification Program Preparation Course

December, 2012 | Sleep Disorders Diagnosis and Treatment Course

DBS Application Training and Course – Dubai

Professional Memberships

Turkish Medical Association

Turkish Neurology Association

Turkish Sleep Medicine Association

Awards & Recognitions

2014 | Düzce University Rectorship – Publication Success Incentive Award

Associate Professor Dr. Yusuf AÇIKGÖZ
Specialization: Medical Oncology

Education:

• 2004-2011: İnönü University Faculty of Medicine
• 2011-2016: Ankara Numune Training and Research Hospital, Internal Medicine
• 2017-2022: Health Sciences University, Medical Oncology

Professional Experience:

• 2016-2017: Bingöl City Hospital, Internal Medicine
• 2021-2022: Health Sciences University, Medical Oncology
• 2022-2023: Kastamonu Education and Research Hospital, Medical Oncology
• 2023-2024: Ohio State University, Medical Oncology
• 2024-Present: Lokman Hekim University, Medical Oncology, Ankara Hospital

Clinical Trials, Courses, Certifications:

Clinical Trials:

• 2017-2021: Phase III, CheckMate-649 Study (Assistant Investigator)
• 2022-Present: Phase III, Fortitude-101 Study (Assistant Investigator)

Courses:

• 2018: Medicres Basic and Advanced Biostatistics Training Program (ongoing), Istanbul-Vienna
• 2019: Immuno-Oncology Education Course, March 1-2, 2019, Vienna, Central European Cooperative Oncology Group (CECOG)
• 2018: Good Clinical Practice Certification, April 7-8, 2018, Ankara, Health Sciences University
• 2017: Basic Oncology Training Program, November 25-26, 2017, Adana, Clinical Oncology Society
• 2016: Basic Ultrasonography Course (10 hours theoretical + 10 hours practical), September 24-25, 2016, Ankara, Turkish Emergency Medicine Association

Certifications:

• Ongoing: ECFMG Certification
• 2024: CITI Responsible Conduct of Research (The Ohio State University)
• 2024: CITI IACUC-Laboratory Animal Research (The Ohio State University)
• 2024: CITI Human Subjects Protection (The Ohio State University)
• 2024: CITI Good Clinical Practice (The Ohio State University)
• 2023: Occupational English Test (OET)
• 2019: International English Language Testing System (IELTS), Total Score: 6.5, May 26, 2019, Ankara, British Council
• 2017: USMLE Step 2 CK Exam; Score: 244, February 7, 2017
• 2016: USMLE Step 1 Exam; Score: 215, August 25, 2016

Memberships:

• American Society of Clinical Oncology (ASCO) - 2022
• Turkish Society of Medical Oncology - 2020

Since 1998 he has been Director of the Epilepsy Unit at the Ruber International Hospital in Madrid, a pioneering centre for the diagnosis, medical and surgical treatment of epilepsy in children and adults.

More than 150 neurologists and neurophysiologists from Spain and Latin America have been trained here, and several of its students have successfully opened epilepsy centres in other public and private hospitals, both in Spain and abroad.

The program he directs has become a pioneer in Spain in the field of genetic diagnosis of complex epilepsies and advanced treatments such as drug repositioning, interstitial laser treatment, deep electrodes and gamma radiosurgery, which are used in patients with refractory epilepsy.

Dr. Antonio Gil-Nagel is a professor at the IE University, is an Ad Honorem Professor at the Center for Biomedical Technology of the Polytechnic University of Madrid (CTB) and is Director of the Epilepsy Department at the Francisco Vitoria University of Madrid.

He was a founding member of the European Epilepsy Research Network and the European Association for Epilepsy Monitoring. He is also active in international research projects such as EpiCare and the European Epilepsy Brain Bank and has held relevant positions in international institutions such as the International Bureau for Epilepsy (IBE), the International League Against Epilepsy (ILAE), the European Federation of Neurological Societies (EFNS) and the World Federation of Neurology (WFN).

Dr. Gil-Nagel has directed numerous clinical trials and research studies in the field of epilepsy, especially in orphan epilepsies such as Dravet syndrome, Lennox-Gastaut syndrome and other epileptic and developmental encephalopathies. The Epilepsy Program he directs is an international benchmark in the development of pharmacological research. He has been the Principal Investigator of phase II and III clinical trials, including numerous clinical trials and non-pharmacological treatments (epilepsy surgery, electrical stimulation, ketogenic diet and gamma knife). His research is funded by European Union funds and the Public Innovation Agency of the Ministry of Science and Innovation of the Spanish Government. Their dedication to research and the development of new treatments allows them to accelerate the treatment of their patients with new treatments.

In addition to being a frequent speaker at national and international conferences, he has authored several books on epilepsy and electroencephalography and has numerous publications on epilepsy in journals such as Annals of Neurology, Brain, Epilepsy, European Journal of Neurology, Journal of Neurology, Nature Neurology, Neurology, and the New England Journal of Medicine, among others. He has authored 165 Scopus-indexed articles with 5,265 citations and an h-index of 35.

In 2021, his team received the Innovative Small and Medium Enterprise Award for the project on mesial temporal lobe epilepsy and encephalocele (Ministry of Science and Innovation, Spain), and in 2012, the Scientific Award from the Epilepsy Group of the Spanish Society of Neurology (SEN).

Education

• 1985 – Bachelor of Medicine and Surgery , Complutense University of Madrid.
• 1986-1989 – Specialization in Neurology , Hospital 12 de Octubre, Madrid.
• 1991–1993 – Epilepsy Specialist , Comprehensive Epilepsy Program, University of Minnesota, Minneapolis, USA.
• 1997 – Certification of the American Board of Clinical Neurophysiology .

Professional experience

• 1993–1995 – Associate Professor, Epilepsy Program, Department of Neurology, University of Minnesota, Minneapolis, USA.
• 1995–1998 – Associate Professor, Epilepsy Program, Department of Neurological Sciences, Rush-Presbyterian-St. Luke's Medical Center, Chicago, USA.
• Since 1998 – Director of the Epilepsy Program , Neurology Service, Ruber International Hospital, Madrid.
• 2014 – Defense of the dissertation on the topic: "Clinical and neurophysiological studies in the pre-surgical evaluation of epilepsy" , Complutense University of Madrid.
• 2022 – Deputy Head of the Neurology Service , Ruber Internacional International Hospital, Madrid.

Membership in professional societies

• Since 1991 – Member of the American Academy of Neurology (AAN).
• Since 1991 – Member of the American Epilepsy Society (AES).
• Since 1996 – Member of the American Society of Clinical Neurophysiology .
• Since 1988 – Member of the Spanish Society of Neurology .
• Since 2006 – Representative of Spain in the World Federation of Neurology (WFN).
• Since 2006 – Member of the editorial committee and the WFN web portal .
• Since 2008 – Director of the Epilepsy Group of the European Federation of Neurological Societies (EFNS).
• Since 2009 – Member of the EFNS Educational Courses Committee.
• 2007–2009 – Member of the EFNS Scientific Committee .
• 2007–2008 – Vice-President of the Scientific Committee of the 12th EFNS Congress , Madrid.
• 2004–2007 – Delegate of Spain to the EFNS .
• 2009 – Member of the Scientific Committee of the World Congress of Neurologists , Marrakech.

Outstanding Achievements

Dr. Hill-Nagel is a leading international figure in the field of epileptology, a recognized expert in the diagnosis and treatment of genetic epilepsy and the surgical approach to its correction. His distinguished professional career includes many years of experience in leading medical institutions in the United States and Europe, as well as active participation in international research and educational programs.

Dr. Hill-Nagel not only advances the science of neurology on a global level, but also successfully implements cutting-edge treatment methods, improving the lives of thousands of patients around the world.

Dr. Mustafa Yavuz Samanci is an Associate Professor of Neurosurgery at Medipol Acıbadem District Hospital in Istanbul. He has specialized training in stereotactic, functional, and pediatric neurosurgery. Dr. Samanci completed a clinical fellowship in Gamma Knife Radiosurgery. He has also finished advanced programs in spinal cord and peripheral nerve stimulation. He received several TÜBİTAK postdoctoral research fellowships and the Prof. Dr. Hakan Caner Overseas Education Scholarship from the Turkish Neurosurgical Society.

Dr. Samanci is an active member of several national and international neurosurgical societies. These include the Turkish Neurosurgical Society, the International Parkinson and Movement Disorder Society, and the European Society for Stereotactic and Functional Neurosurgery. He has served on editorial boards and scientific committees. His work reflects significant contributions to academic neurosurgery and research.

Education and Expertise

1988: Istanbul University Cerrahpaşa Faculty of Medicine, Medical Education, Istanbul

1996: Haydarpaşa Numune Training and Research Hospital, Brain and Neurosurgery Clinic, Neurosurgery Specialist Training, Istanbul

Experience

1989 to 1996: Haydarpaşa Numune Training and Research Hospital, Brain and Neurosurgery Clinic, Assistant Doctor, Istanbul

1996 to 1999: Private Respect Hospital, Specialist Doctor and Chief Physician, Istanbul

2000 to 2002: Bakırköy Mental and Neurological Diseases Training and Research Hospital, 1st Neurosurgery Clinic, Specialist Doctor, Istanbul

2002 to 2010: Ministry of Health Pendik State Hospital, Specialist Doctor, Istanbul

2008 to 2009: Participation in "Spinal Surgery Program" at Istanbul American Hospital Neurosurgery Clinic. Fellowship Days: 01.05.2008 - 31.12.2009

2010 to 2011: University of California Los Angeles (UCLA), Santa Monica Hospital Center for Spinal Surgery (Comprehensive Spine Center), Researcher (Fellow), California, USA

2011: Associate Professor

2014: Virginia University Faculty of Medicine, Department of Brain and Neurosurgery, Visiting Faculty Member, Charlottesville, Virginia, USA

2012 to 2016: Istanbul Medeniyet University Faculty of Medicine, Department of Brain and Neurosurgery, Istanbul

2016 to 2018: Vital Fulya Plaza, Fulya/Beşiktaş/Istanbul

Professional Memberships

-Turkish Neurosurgery Association
-Turkish Neurosurgery Association, Spinal and Peripheral Nerve Surgery Teaching and Training Group
-Turkish Spine Association
-AO Spine International
-Society for Minimal Intervention in Spinal Surgery
-Turkish Neurosurgery Association, Surgical Neurosurgery Group
-Scoliosis Research Society (SRS)

 

EDUCATION:

2015

Uludag University, Ophthalmology

2008

Eskisehir Osmangazi University, Faculty of Medicine

2001

Kırıkkale Science High School, Numerical

EXPERIENCE:

2019 Gazi University Faculty of Medicine Ophthalmology (Vitreo-Retinal Surgery and Medical Retina Fellowship)

2016 SBÜ Zekai Tahir Burak EAH (Retinopathy of Prematurity Fellowship)/

2015 - 2023 Kocaeli Derince Training and Research Hospital

2023 - Medipol University Pendik Hospital

Education

2005 – 2011 | Kocaeli University, Faculty of Medicine, Kocaeli, Turkey
M.D. Degree

2013 – 2019 | Erenköy Mental Health and Neurology Training and Research Hospital, Istanbul, Turkey
Neurology Residency Program

Languages

English – Very Advanced

Professional Experience

Artvin Borçka State Hospital, Artvin, Turkey
General Practitioner (Compulsory Service)
2011 – 2012

Erenköy Mental Health and Neurology Training and Research Hospital, Neurology Department, Istanbul, Turkey
Resident Physician
2013 – 2019

Siirt State Hospital, Siirt, Turkey
Neurology Specialist (Compulsory Service)
2019 – March 2021

Private Pendik Medical Park Hospital, Istanbul, Turkey
Neurology Specialist
April 3, 2021 – April 10, 2024

Bahçeşehir University Faculty of Medicine, Department of Neurology, Istanbul, Turkey
Assistant Professor
April 19, 2021 – June 1, 2024

Medipol Acıbadem Regional Hospital, Istanbul, Turkey
Associate Professor of Neurology
April 22, 2024 – Present

Istanbul Medipol University Faculty of Medicine, Department of Neurology, Istanbul, Turkey
Associate Professor of Neurology
November 11, 2024 – Present

Memberships

Turkish Neurology Society

Turkish Medical Association

International Parkinson and Movement Disorder Society

Turkish Neurology Society Neurorehabilitation Working Group

Global Migraine and Pain Society

International Headache Society

Turkish Parkinson’s Disease Society

Turkish Alzheimer Association, Kadıköy Branch

Areas of Interest

Parkinson’s disease and other movement disorders

Migraine and other headache disorders

Sleep disorders

Dementia and Alzheimer’s disease

EEG, Polysomnography (PSG), Multiple Sleep Latency Test (MSLT)

Botulinum toxin injections for movement disorders

Nerve blocks and botulinum toxin for headache management

Epilepsy

Dr. Fatma Gulhan Sahbaz is a neurologist. She graduated from Manisa Celal Bayar University Faculty of Medicine. She completed her neurology residency at SBÜ Istanbul Kartal Dr. Lütfi Kırdar Training and Research Hospital. Dr. Sahbaz has served as Clinic Chief at Afyonkarahisar State Hospital. She currently practices at İzmir Ekonomi University Medical Point Hospital.

She treats many neurological conditions, including Alzheimer’s disease, ALS, epilepsy, cerebrovascular diseases, brain tumors, movement disorders, and headaches. Dr. Sahbaz is experienced in advanced treatments such as acute stroke intervention, deep brain stimulation, IVIG therapy, and botulinum toxin injections.

She is a member of the Turkish Neurology Society, International Parkinson and Movement Disorder Society, and European Academy of Neurology.

Education and Expertise

• 1999 – 2005 – FIRAT UNIVERSITY FACULTY OF MEDICINE
• 1995 – 1999 – IZMIR ATATURK HIGH SCHOOL

Diseases

• Alzheimer’s type dementia
• Headaches
• Dizziness
• Cerebrovascular diseases
• Vascular diseases
• Dementia Diseases
• Demyelinating Diseases
• Epilepsy
• Movement Disorders
• Migraine
• Myopathies
• MOGAD

Treatment Methods

• Botox
• Duodopa Treatment
• Intravenous Thrombolytic
• IVIG Treatment
• Migraine vaccine
• Migraine Botox

Experience

• 2005-2010 – Ege University Faculty of Medicine, Department of Neurology, Specialization Student, Izmir.
• 2010-2012 – İzmir Tire State Hospital Neurology Department
• September 2012 – May 2013 – Çanakkale 18 March University, Faculty of Medicine, Department of Neurology, Assistant Professor.
• 2013 – Medical Point Izmir Hospital Neurology Department

Professional Memberships

• Turkish Neurology Association

Dr. Yan Zhi Ping is the Director of the Radiology Department at Xiamen Humanity Hospital. He graduated from the First Military Medical University. He has authored more than 30 papers. He has edited and contributed to several monographs. He received a Fujian Provincial Third Prize for Science and Technology Progress and two Xiamen Municipal Second Prizes. His expertise includes CT and MRI of the central nervous system, musculoskeletal system, thoracic, and abdominal diseases. He also focuses on cerebral functional imaging. He is skilled in the early diagnosis and differential diagnosis of lung cancer and brain tumors.

Appointments: Standing Committee Member of the Radiology Branch of the Fujian Association of Integrative Medicine. Standing Committee Member of the Fujian Radiological Society. Vice Chairman of the Xiamen Radiological Society. Vice Chairman of the Radiology Branch of the Xiamen Medical Doctor Association. Deputy Director of the Xiamen Radiology Quality Control Center.

Dr. Yang Seyeon is a neurosurgeon specializing in ischemic stroke, intracerebral hemorrhage, cerebral aneurysm, moyamoya disease, carotid artery stenosis, vascular dizziness, and head trauma. Dr. Yang is the Head of the Department of Neurosurgery at Naeun Hospital.

Dr. Yang graduated from The Catholic University and earned a Master of Medicine. Dr. Yang completed an internship and a neurosurgery residency at the Catholic Medical Center. Dr. Yang served as a neurosurgery fellow at Uijeongbu St. Mary’s Hospital and worked at its Regional Trauma Center. Dr. Yang also served as a dedicated neurosurgery specialist.

Dr. Yang served as a Clinical Assistant Professor of Neurosurgery at Uijeongbu St. Mary’s Hospital. Dr. Yang also served as Head of Neurosurgery at G‑Sam Hospital.

Dr. Mehmet Tonge is a neurosurgeon with expertise in Stereotactic and Functional Neurosurgery. He specializes in MR Guided Focused Ultrasound, deep brain stimulation, Gamma Knife Radiosurgery, and surgery for movement disorders, pain, and spasticity.

Dr. Tonge has published 32 articles in international and national journals and written 12 book chapters. He has presented 92 oral and poster presentations and delivered 41 invited lectures. He completed a Deep Brain Stimulation Fellowship at Maastricht University and finished the 4-year EANS training cycle. Dr. Tonge is known for his research and clinical work in functional neurosurgery.

Professional experience

Since 2006, he has been Head of the Neurology Department at the Quironsalud University Hospital of Madrid and the Ruber Juan Bravo Hospital.

Professor of Medicine at the Faculty of Biomedical Sciences of the European University of Madrid, holds the national accreditation of Professor of Medical Sciences (issued by ANECA).

Doctor of Medicine, Complutense University of Madrid (UCM). Award for Outstanding Doctoral Thesis (UCM, 2004): Study on the relationship of human herpes virus 6 as an environmental factor in multiple sclerosis.

Membership in scientific societies

National and International Principal Investigator in Neuroscience at Quironsalud Madrid (June 2015 – present)

President of the Research Committee of the Quironsalud University Hospital of Madrid (2012 to present).

Member of the Research Committee of the San Carlos Clinical Hospital (2012-2015).

Member of the Council of the Faculty of Medicine of the Complutense University of Madrid (2011-2015).

Research and Teaching

Principal investigator of 100 national and international clinical trials.

7 FIS research projects from the Carlos III Institute of Health (the last 5 as principal investigator).

10 projects from private foundations, received on a competitive basis (7 as principal investigator).

He has authored 139 international articles with a total impact factor of 949,917 and 4,552 citations. 38 books and book chapters with an H-factor of 34 (2018).

His publications stand out in journals that have the greatest global impact on research, such as the New England Journal of Medicine and the Lancet.

Dr. Rafael Arroyo has given over 300 international and national presentations at various Congresses.

Education :

Professor of Medicine at the Faculty of Biomedical Sciences of the European University of Madrid and holds the national accreditation of Professor of Medical Sciences (issued by ANECA).

PROFESSIONAL EXPERIENCE

2011-2012
Erzurum Koprukoyu State Hospital
Department: General Medicine

2012-2017
Istanbul University Cerrahpaşa Medical Faculty
Department: Internal Medicine

06/2017-10/2017
Istanbul Gaziosmanpasa Taksim Training and Research Hospital
Department: Internal Medicine

10/2017-11/2018
Istanbul University Istanbul Medical Faculty
Department: Allergy and Immunology Fellowship

2018/2022
Istanbul University Oncology Institute
Department: Medical Oncology Fellowship

2022-2023
Tekirdag City Hospital
Department: Medical Oncology Specialist

2023-present
Istanbul Medipol University Medipol Bahcelievler Private Hospital
Department: Medical Oncology Assoc. Prof.

EDUCATION

2005-2011
Medical Education
Sivas Cumhuriyet University Medical Faculty, Sivas, Turkey

2012-2017
Internal Medicine
Istanbul University Cerrahpaşa Medical Faculty, Department of Internal Medicine, Istanbul, Turkey

2017-2018
Allergy-Immunology Fellowship
Istanbul University Istanbul Medical Faculty
Department of Internal Medicine, Division of Allergy and Immunology, Istanbul, Turkey

2018-2022
Medical Oncology Fellowship
Istanbul University Oncology Institute, Department of Medical Oncology, Istanbul, Turkey

2022
ESMO Board Certification in Medical Oncology
10th September 2022 in Paris, France.

2023
Medical Oncology Assoc. Prof.
Istanbul Medipol University Department of Medical Oncology, Istanbul, Turkey

INTERNATIONAL CLINICAL TRIALS:

1. Astefania - ROCHE

• Title: A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
• Role: Subinvestigator

2. PFİZER

• Title: A Study Of Lorlatinib Versus Crizotinib In First-Line Treatment Of Patients With ALK-Positive NSCLC
• Role: Subinvestigator

3. RECITE - AMGEN

• Title: Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer
• Role: Subinvestigator

4. NAVIGATE - BAYER

• Title: A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors
• Role: Subinvestigator

5. RUBY - Tesaro (PRA)

• Title: A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer
• Role: Subinvestigator

6. ENGOT-ov43/GOG-3036 - MSD

• Title: Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK001/ENGOT-ov43/GOG-3036)
• Role: Subinvestigator

7. ASTRA ZENECA

• Title: To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.
• Role: Subinvestigator

8. ROSY-O - ASTRA ZENECA

• Title: Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
• Role: Subinvestigator
•  

INTERNATIONAL PUBLICATIONS

I. Published journal articles indexed by SCI, SSCI, and AHCI

Weekly Paclitaxel in Classic Kaposi Sarcoma

• Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Ahmed, M. A., Karaman, S., & Aydiner, A.
• Journal: Medicine, 102(5)

Carboplatin Desensitization in Ovarian Carcinoma

• Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Yildiz, A., Ak, N., & Aydiner, A.
• Journal: Medicine, 101(45), e31726

High-Dose Chemotherapy for Ewing’s Sarcoma

• Authors: Paksoy, N., Ferhatoglu, F., Dogan, İ., Khanmammadov, N., Celik, A. I., Gulbas, Z., & Başaran, M.
• Journal: Medicine, 101(49), e32213

Multidrug Refractory TFE3(+) Renal Cell Carcinoma

• Authors: Paksoy, Nail, et al.
• Journal: Journal of Oncology Pharmacy Practice, 2022, 28.1: 215-221

Crizotinib Efficacy in NSCLC with MET Alterations

• Authors: Gürbüz, M., Kiliçkap, S., Bilici, A., Karadurmuş, N., Sezer, A., Şendur, M. A. N., ... & Demirkazik, A.
• Journal: Medicine, 101(50), e32368

Clinicopathological Features in ALK Mutant NSCLC

• Authors: Dogan, I., Gurbuz, M., Paksoy, N., Ferhatoglu, F., Vatansever, S., Saip, P., ... & Aydiner, A.
• Journal: Medicine, 101(34)

PSMA-Based Tumor Burden in Prostate Cancer

• Authors: HAS SIMSEK, Duygu, et al.
• Journal: Annals of Nuclear Medicine, 2021, 35.6: 680-690

Atezolizumab in Metastatic Urothelial Carcinoma

• Authors: TURAL, Deniz, et al.
• Journal: European Urology Focus, 2021, 7.5: 1061-1066

Pulmonary Sarcomatoid Carcinoma

• Authors: FERHATOGLU, Ferhat, et al.
• Journal: Oncology Research and Treatment, 2021, 44.11: 590-601

Prognostic Factors in Atezolizumab-Treated Urothelial Carcinoma

• Authors: TURAL, Deniz, et al.
• Journal: International Journal of Clinical Oncology, 2021, 26.8: 1506-1513

Atezolizumab with Chemotherapy in Small Cell Lung Cancer

• Authors: GÜRBÜZ, Mustafa, et al.
• Journal: Journal of Cancer Research and Clinical Oncology, 2022, 1-9

FOLFIRINOX vs. Gemcitabine + Nab-Paclitaxel in Pancreatic Cancer

• Authors: AY, Seval, et al.
• Journal: Journal of Chemotherapy, 2022, 1-7

Trastuzumab Emtansine in Older HER2-Positive Breast Cancer Patients

• Authors: CIL, Ibrahim, et al.
• Journal: Tumori Journal, 2022, 108.1: 19-25

Real-Life Efficacy of Osimertinib in Advanced NSCLC

• Authors: HIZAL, Mutlu, et al.
• Journal: Journal of Cancer Research and Clinical Oncology, 2022, 148.6: 1501-1508

ALK-Positive Cells Percentage and Alectinib Efficacy

• Authors: Hizal, M., Bilgin, B., Paksoy, N., Atcı, M. M., Kahraman, S., Kılıçkap, S., ... & Şendur, M. A. N.
• Journal: Journal of Cancer Research and Clinical Oncology, 149(8), 4141-4148

Real-World Data on Alectinib in ALK-Positive NSCLC

• Authors: Hizal, M., Bilgin, B., Paksoy, N., Kılıçkap, S., Atcı, M. M., Kahraman, S., ... & Şendur, M. A. N.
• Journal: Future Oncology, 18(23), 2573-2582

Prognostic Factors in Metastatic RCC with T790M Mutation

• Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

FLOT Regimen in Metastatic Gastric Cancer

• Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
• Journal: Journal of Cancer Research and Therapeutics

Desensitization Protocol in Lenalidomide Hypersensitivity Reactions

• Authors: DEMIR, Semra, et al.
• Journal: Annals of Allergy, Asthma & Immunology, 2019, 123.4: 394-397

Factors Associated with Diagnostic Skin Test Positivity in PPI Hypersensitivity

• Authors: ÖZDEMIR, Seçil Kepil, et al.
• Journal: Allergy, 2019, 74.6: 1187-1190

Efficacy of Capecitabine and Temozolomide in Neuroendocrine Tumors

• Authors: Ünal, Ç., Azizy, A., Karabulut, S., Taştekin, D., Akyıldız, A., Yaşar, S., ... & Sağlam, S.
• Journal: The Oncologist, oyad257

Subsequent Treatments in Hormone-Positive Breast Cancer Progression

• Authors: Karacin, C., Oksuzoglu, B., Demirci, A., Keskinkılıç, M., Baytemür, N. K., Yılmaz, F., ... & Hacıbekiroğlu, İ.
• Journal: BMC cancer, 23(1), 192

Termination of Trastuzumab in HER2-Positive Metastatic Breast Cancer

• Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Saip, P., & Aydiner, A.
• Journal: Scientific Reports, 13(1), 8779

Long-term Outcomes and Predictors of Recurrence in Node-Negative Early Stage Breast Cancer

• Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Ferhatoğlu, F., Ak, N., ... & Aydiner, A.
• Journal: Journal of Cancer Research and Clinical Oncology, 1-9

Prognostic Factors Influencing PFS in HER2-Positive Metastatic Breast Cancer

• Authors: Doğan, İ., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydıner, A.
• Journal: European Journal of Breast Health, 19(2), 128

Treatment Efficacy of Ribociclib or Palbociclib plus Letrozole in Metastatic Breast Cancer

• Authors: Kahraman, S., Erul, E., Seyyar, M., Gumusay, O., Bayram, E., Demirel, B. C., ... & Nahit Sendur, M. A.
• Journal: Future Oncology, 19(10), 727-736

Efficacy and Safety of Sorafenib in Adult Metastatic Osteosarcoma Patients

• Authors: Dogan, I., Paksoy, N., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

Single-Agent Temozolomide as Salvage Therapy in Heavily Pretreated Metastatic Sarcoma Patients

• Authors: Dogan, I., Paksoy, N., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

Outcomes and Prognostic Factors in Metastatic Renal Cell Carcinoma with Brain Metastases

• Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

FLOT Regimen in First-Line Treatment of Metastatic Gastric Cancer

• Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
• Journal: Journal of Cancer Research and Therapeutics

Prognostic Factors of Perioperative FLOT Regimen in Operable Gastric Cancer

• Authors: Erol, C., Sakin, A., Basoglu, T., Ozden, E., Cabuk, D., Dogan, M., ... & Sendur, M. A. N.
• Journal: [Not specified]

Efficacy and Outcomes of Systemic Chemotherapy in Posttransplant Kaposi Sarcoma

• Authors: Khanmammadov, N., Paksoy, N., Doğan, I., Ferhatoğlu, F., Saip, P., & Aydiner, A.
• Journal: Medicine, 102(39), e35383

Comparison of Second-Line Treatments in Metastatic Renal Cell Carcinoma

• Authors: Pehlivan, M., Paksoy, N., Aydin, E., Basaran, M., & Ekenel, M.
• Journal: Medicine, 102(41), e35245

Toxicity Management and Effectiveness of Regorafenib in Advance GIST Patients: A Real-world Study - Authors: Paksoy, N., Ferhatoğlu, F., Doğan, İ., Khanmammadov, N., Bozbey, H. U., Karabulut, S., & Taştekin, D. - Journal: TURKISH JOURNAL OF ONCOLOGY, 1(1)

Demographic and Clinical Features and Factors Associated with Survival in Patients with Primary Glomerulonephritis: Single Tertiary Center Experience - Authors: Paksoy, N., Trabulus, S., Seyahi, N., & Altiparmak, M. R. - Journal: Namik Kemal Tip Dergisi, 11(1)

Efficacy of Sorafenib in Symptomatic Patients with Pretreated Progressive Desmoid Tumors - Authors: Paksoy, N., Ferhatoglu, F., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M.

Nodal Response to Neoadjuvant Chemotherapy is a Better Predictive Factor of Survival Than Miller-Payne Scoring in Breast Cancer - Authors: Ak, Naziye, et al. - Journal: Journal of Oncological Sciences, 7.2: 42-49

Evaluation of Prognostic and Predictive Values of Hemogram Parameters in Patients with Advanced Stage Ovarian Carcinoma - Authors: Ak, Naziye, et al. - Journal: Turkish Journal of Oncology/Türk Onkoloji Dergisi, 2021, 36.4

Identifying Risk Factors Associated with Survival and Drug-Related Toxicities in Imatinib-Resistant Gastrointestinal Stromal Tumor (GIST) Patients Treated with Sunitinib - Authors: Ferhatoglu, F., Karabulut, S., Paksoy, N., & Tastekin, D.

Real-life Outcomes of ROS1 Fusion-positive Metastatic Lung Cancer Patients who were Treated with Crizotinib - Authors: Dogan, İ., Khanmammadov, N., Paksoy, N., Ferhatoglu, F., Aydın, E., Vatansever, S., & Aydine, A. - Journal: TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY

Predictors of the acquisition of T790M mutation in EGFR-mutant metastatic lung cancer patients who were treated with EGFR inhibitors - Authors: Dogan, I., Khanmammadov, N., Paksoy, N., Vatansever, S., Saip, P., & Aydıner, A. - Journal: Eurasian Journal of Pulmonology

Laterality of Adrenal Gland Metastasis in Lung Cancer: Results of a Comparative Study - Authors: Ferhatoglu, F., Gagatay, T., Okumus, G., Aydiner, A., Paksoy, N., Ak, N., ... & Saip, P. - Journal: Eurasian Journal of Medical Investigation, 7(2)

Poor Risk Factors Affecting Cancer Patients Infected with Covid-19: A Retrospective Comparative Study from a Pandemic Hospital - Authors: Ferhatoglu, F., Kapağan, T., Paksoy, N., Ak, N., Medetalibeyoğlu, A., Şenkal, N., ... & Vatansever, S. - Journal: Turk Onkoloji Dergisi, 38(1)

Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center - Authors: Ferhatoglu, F., Paksoy, N., & Başaran, M. - Journal: Namik Kemal Tip Dergisi, 10(4)

Evaluation of clinical features and risk factors related to late recurrence (> 5 years) in patients with breast cancer - Authors: Ferhatoglu, F., Aydiner, A., & Paksoy, N. - Journal: Journal of Surgery & Medicine (JOSAM), 6(12)

Assessing the Clinical Impact of Lutetium-177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) on Metastatic Neuroendocrine Tumors: A Multicenter Real-World Data from Türkiye

Thesis:

Istanbul University Cerrahpaşa Medical Faculty, Internal Medicine Department PAKSOY, Nail. Demographical, clinical characteristics and survival factors in patients withprimary glomerulonephritis: Cerrahpasa Medical Faculty Experience. (2016)

International Refereed Congress / Symposium Publications in Proceedings (ASCO/ESMO Abstracts)

Prognostic factors influencing progression-free survival in HER2 positive metastatic breast cancer patients who treated with lapatinib and capecitabine combination

• Authors: Dogan, I., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydiner, A. (2022)

Efficacy of regorafenib and 5-fluorouracil-based rechallenge treatment in the third-line treatment of metastatic colorectal cancer: A Turkish oncology group study

• Authors: Şenocak Taşçi, E., Oyan, B., Sonmez, O., Mutlu, A. U., Atcı, M. M., Oner, I., ... & Gulmez, A. (2022)

Long-term outcomes and predictors of recurrence in patients with early-stage node-negative breast cancer

• Authors: Dogan, I., Aydin, E., Paksoy, N., Ferhatoglu, F., Ak, N., Ibis, K., ... & Aydiner, A. (2021)

Efficacy of temozolomide in pretreated patients with metastatic sarcoma

• Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

Efficacy of sorafenib in symptomatic patients with pretreated progressive desmoid tumors

• Authors: Ferhatoglu, F., Paksoy, N., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M. (2021)

Efficacy of sorafenib in heavily pretreated adult patients with metastatic osteosarcoma

• Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

Outcomes and prognostic factors in metastatic renal cell carcinoma patients with brain metastases

• Authors: Dogan, İ., Iribas, A., Paksoy, N., Ekenel, M., Vatansever, S., & Basaran, M. (2021)

Association of response to first-line chemotherapy with the efficacy of atezolizumab in patients with metastatic urothelial carcinoma

• Authors: Tural, D., Olmez, O. F., Sümbül, A. T., Artac, M., Ozhan, N., Akar, E., ... & Erman, M. (2021)

Safety and survival in adult women with platinum-sensitive relapsed BRCA mutant ovarian cancer: A study of patients in Olaparib Turkey Early Access Program—LynTurk study

• Authors: Esin, E., Ahmed, M. A., Yıldırım, H. Ç., Mandel, N. M., Erdemoglu, E., Sari, M., ... & Paydas, S. (2023)

Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: Results of real-life experiences

• Authors: Tural, D., Ölmez, Ö. F., Sümbül, A. T., Artaç, M., Özhan, N., Akar, E., ... & Kılıçkap, S. (2021)

Dr. Irfan Cicin is a Professor of Medical Oncology at the Trakya University Faculty of Medicine (2015–present). He has over 20 years of medical oncology experience and has held academic roles since 2010.

Education: MD, Istanbul University – Cerrahpaşa (1991–1997). Residency in Internal Medicine, Trakya University (1997–2002). Fellowship in Medical Oncology, Trakya University (2002–2004).

Practice: Medical Oncologist, Trakya University (2005–2008). Medical Oncologist, Elazığ Training and Research Hospital (2008–2010). Associate Professor of Medical Oncology, Trakya University (2010–2015). He previously served as a physician in the Turkish Air Force at Etimesgut Military Hospital (2004–2005).